Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
23:26:45 EDT Wed 02 Sep 2026
Enter Symbol
or Name
USA
CA



Q:FBIO - FORTRESS BIOTECH INC - https://fortressbiotech.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
FBIO - Q0.12.47·2.800.12.73+0.051.9279.86721,6392.67  2.74  2.674.53  2.1819:30:06Aug 1315 min RT 2¢

Recent Trades - Last 10 of 1639
Time ETExPriceChangeVolume
19:30:06Q2.730.051
19:30:06Q2.730.051
19:30:04Q2.730.051
19:30:04Q2.730.051
19:18:16Q2.730.055
16:15:00Q2.730.051
16:15:00Q2.730.051
16:10:04Q2.730.051
16:10:04Q2.730.051
16:10:04Q2.730.051

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-08-13 16:05U:FBIONews ReleaseFortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
2026-08-12 16:01U:FBIONews ReleaseJourney Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights
2026-08-05 08:30U:FBIONews ReleaseJourney Medical Corporation to Announce Second Quarter 2026 Financial Results on August 12, 2026
2026-07-27 08:00U:FBIONews ReleaseFortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $130 Million Series B Financing
2026-05-19 16:45U:FBIONews ReleaseJourney Medical Corporation to Participate in A.G.P.'s Annual Virtual Healthcare Conference
2026-05-18 08:30U:FBIONews ReleaseFortress Biotech to Participate in A.G.P.'s Annual Virtual Healthcare Conference
2026-05-14 16:10U:FBIONews ReleaseFortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
2026-05-13 16:01U:FBIONews ReleaseJourney Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights
2026-05-06 16:01U:FBIONews ReleaseJourney Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026
2026-05-04 08:30U:FBIONews ReleaseFortress Biotech to Participate in the H.C. Wainwright 2nd Annual Royalty Company Virtual Conference
2026-04-21 08:30U:FBIONews ReleaseJourney Medical Corporation Secures Contract with Third Major GPO for Emrosi(TM)
2026-03-31 16:05U:FBIONews ReleaseFortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights
2026-03-30 16:05U:FBIONews ReleaseFortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million
2026-03-25 16:01U:FBIONews ReleaseJourney Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights
2026-03-18 08:30U:FBIONews ReleaseJourney Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026
2026-02-23 09:24U:FBIONews ReleaseUPDATE: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
2026-02-23 08:30U:FBIONews ReleaseFortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million
2026-02-23 08:00U:FBIONews ReleaseAvenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease
2026-01-13 07:45U:FBIONews ReleaseFortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO(TM) (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States
2025-12-15 08:00U:FBIONews ReleaseFortress Biotech and Cyprium Therapeutics Announce FDA Acceptance of CUTX-101 NDA Resubmission